{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:09:35Z","timestamp":1793642975690,"version":"4.5.1"},"reference-count":51,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Albuminuria, routinely assessed as spot urine albumin-to-creatinine ratio (UACR), indicates structural damage of the glomerular filtration barrier and is associated with poor kidney and cardiovascular outcomes. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been found to reduce UACR in patients with type 2 diabetes, but its use in patients with heart failure (HF) is less well studied.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To analyze the association of empagliflozin with study outcomes across baseline levels of albuminuria and change in albuminuria in patients with HF across a wide range of ejection fraction levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This post hoc analysis included all patients with HF from the EMPEROR-Pooled analysis using combined individual patient data from the international multicenter randomized double-blind parallel-group, placebo-controlled EMPEROR-Reduced and EMPEROR-Preserved trials. Participants in the original trials were excluded from this analysis if they were missing baseline UACR data. EMPEROR-Preserved was conducted from March 27, 2017, to April 26, 2021, and EMPEROR-Reduced was conducted from April 6, 2017, to May 28, 2020. Data were analyzed from January to June 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Randomization to empagliflozin or placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>New-onset macroalbuminuria and regression to normoalbuminuria and microalbuminuria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 9673 patients were included (mean [SD] age, 69.9 [10.4] years; 3551 [36.7%] female and 6122 [63.3%] male). Of these, 5552 patients had normoalbuminuria (UACR &amp;amp;lt;30 mg\/g) and 1025 had macroalbuminuria (UACR &amp;amp;gt;300 mg\/g). Compared with normoalbuminuria, macroalbuminuria was associated with younger age, races other than White, obesity, male sex, site region other than Europe, higher levels of N-terminal pro\u2013hormone brain natriuretic peptide and high-sensitivity troponin T, higher blood pressure, higher New York Heart Association class, greater HF duration, more frequent previous HF hospitalizations, diabetes, hypertension, lower eGFR, and less frequent use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and mineralocorticoid receptor antagonists. An increase in events was observed in individuals with higher UACR levels. The association of empagliflozin with cardiovascular mortality or HF hospitalization was consistent across UACR categories (hazard ratio [HR], 0.80; 95% CI, 0.69-0.92 for normoalbuminuria; HR, 0.74; 95% CI, 0.63-0.86 for microalbuminuria; HR, 0.78; 95% CI, 0.63-0.98 for macroalbuminuria; interaction <jats:italic>P<\/jats:italic> trend\u2009=\u2009.71). Treatment with empagliflozin was associated with lower incidence of new macroalbuminuria (HR, 0.81; 95% CI, 0.70-0.94; <jats:italic>P<\/jats:italic>\u2009=\u2009.005) and an increase in rate of remission to sustained normoalbuminuria or microalbuminuria (HR, 1.31; 95% CI, 1.07-1.59; <jats:italic>P<\/jats:italic>\u2009=\u2009.009) but not with a reduction in UACR in the overall population; however, UACR was reduced in patients with diabetes, who had higher UACR levels than patients without diabetes (geometric mean for diabetes at baseline, 0.91; 95% CI, 0.85-0.98 and for no diabetes at baseline, 1.08; 95% CI, 1.01-1.16; interaction <jats:italic>P<\/jats:italic>\u2009=\u2009.008).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this post hoc analysis of a randomized clinical trial, compared with placebo, empagliflozin was associated with reduced HF hospitalizations or cardiovascular death irrespective of albuminuria levels at baseline, reduced progression to macroalbuminuria, and reversion of macroalbuminuria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifiers: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03057977\">NCT03057977<\/jats:ext-link> and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03057951\">NCT03057951<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2022.2924","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T15:02:12Z","timestamp":1663772532000},"page":"1148","source":"Crossref","is-referenced-by-count":54,"title":["Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure"],"prefix":"10.1001","volume":"7","author":[{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm, Centre d\u2019Investigations Cliniques Plurith\u00e9matique 1433, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France"},{"name":"Department of Surgery and Physiology, Cardiovascular Research and Development Center, University of Porto, Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm, Centre d\u2019Investigations Cliniques Plurith\u00e9matique 1433, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Research Institute, Dallas, Texas"},{"name":"University of Mississippi Medical Center, Jackson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Pocock","sequence":"additional","affiliation":[{"name":"London School of Hygiene and Tropical Medicine, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Brueckmann","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International, Ingelheim, Germany"},{"name":"First Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Steubl","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International, Ingelheim, Germany"},{"name":"Department of Nephrology, Hospital rechts der Isar, Technical University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Schueler","sequence":"additional","affiliation":[{"name":"mainanalytics, Sulzbach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology Berlin Institute of Health Center for Regenerative Therapies German Centre for Cardiovascular Research partner site Berlin, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Research Institute, Dallas, Texas"},{"name":"Imperial College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"hoi220049r1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrneph.2013.197","article-title":"The role of the glomerular endothelium in albumin handling.","volume":"9","author":"Satchell","year":"2013","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"hoi220049r2","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2174\/1570161118666191224120242","article-title":"The endothelial glycocalyx as a key mediator of albumin handling and the development of diabetic nephropathy.","volume":"18","author":"Korakas","year":"2020","journal-title":"Curr Vasc Pharmacol"},{"issue":"4","key":"hoi220049r3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"hoi220049r4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/j.ajkd.2011.02.391","article-title":"High-normal albuminuria and risk of heart failure in the community.","volume":"58","author":"Blecker","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"hoi220049r5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1056\/NEJM198402093100605","article-title":"Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes.","volume":"310","author":"Mogensen","year":"1984","journal-title":"N Engl J Med"},{"issue":"92","key":"hoi220049r6","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1111\/j.1523-1755.2004.09214.x","article-title":"Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study.","author":"Ibsen","year":"2004","journal-title":"Kidney Int Suppl"},{"issue":"23","key":"hoi220049r7","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1161\/CIRCULATIONAHA.107.723270","article-title":"Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease.","volume":"116","author":"Solomon","year":"2007","journal-title":"Circulation"},{"issue":"4","key":"hoi220049r8","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.2337\/dc20-1622","article-title":"Changes in albuminuria predict cardiovascular and renal outcomes in type 2 diabetes: a post hoc analysis of the LEADER trial.","volume":"44","author":"Persson","year":"2021","journal-title":"Diabetes Care"},{"issue":"1","key":"hoi220049r9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/ki.1987.174","article-title":"Reduction of proteinuria by angiotensin converting enzyme inhibition.","volume":"32","author":"Heeg","year":"1987","journal-title":"Kidney Int"},{"issue":"4","key":"hoi220049r10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.1994.03510280037029","article-title":"Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria.","volume":"271","author":"Viberti","year":"1994","journal-title":"JAMA"},{"issue":"12","key":"hoi220049r11","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"issue":"8","key":"hoi220049r12","doi-asserted-by":"publisher","first-page":"985","DOI":"10.4158\/EP.14.8.985","article-title":"Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors.","volume":"14","author":"Davidson","year":"2008","journal-title":"Endocr Pract"},{"issue":"11","key":"hoi220049r13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005288","article-title":"Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction.","volume":"11","author":"Selvaraj","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"5","key":"hoi220049r14","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"hoi220049r15","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial.","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"31","key":"hoi220049r16","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"1","key":"hoi220049r17","doi-asserted-by":"publisher","first-page":"13009","DOI":"10.1038\/s41598-019-49525-y","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.","volume":"9","author":"Bae","year":"2019","journal-title":"Sci Rep"},{"issue":"6","key":"hoi220049r18","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/dom.12654","article-title":"Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"hoi220049r19","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","article-title":"Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.","volume":"9","author":"Jongs","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"hoi220049r20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9689","key":"hoi220049r21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0140-6736(09)61378-7","article-title":"Albuminuria in chronic heart failure: prevalence and prognostic importance.","volume":"374","author":"Jackson","year":"2009","journal-title":"Lancet"},{"issue":"6","key":"hoi220049r22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure.","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"5","key":"hoi220049r23","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/ejhf.2015.17.issue-5","article-title":"Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.","volume":"17","author":"Voors","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"hoi220049r24","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/ejhf.v22.12","article-title":"Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure.","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"hoi220049r25","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure.","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"hoi220049r26","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1056\/NEJMc2112411","article-title":"Empagliflozin and major renal outcomes in heart failure.","volume":"385","author":"Packer","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"hoi220049r27","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"hoi220049r28","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0272-6386(02)70081-4","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"hoi220049r29","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2337\/dc13-1870","article-title":"Microalbuminuria as a risk predictor in diabetes: the continuing saga.","volume":"37","author":"Bakris","year":"2014","journal-title":"Diabetes Care"},{"issue":"9","key":"hoi220049r30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11886-021-01546-8","article-title":"Intersection between chronic kidney disease and cardiovascular disease.","volume":"23","author":"Laffin","year":"2021","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"hoi220049r31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.7326\/0003-4819-151-1-200907070-00120","article-title":"Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.","volume":"151","author":"Bilous","year":"2009","journal-title":"Ann Intern Med"},{"issue":"4","key":"hoi220049r32","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1681\/ASN.2008040416","article-title":"Supramaximal dose of candesartan in proteinuric renal disease.","volume":"20","author":"Burgess","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"hoi220049r33","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2337\/diacare.23.3.377","article-title":"Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction.","volume":"23","author":"Capes","year":"2000","journal-title":"Diabetes Care"},{"issue":"9386","key":"hoi220049r34","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"hoi220049r35","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"issue":"9386","key":"hoi220049r36","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial.","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"issue":"10","key":"hoi220049r37","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"hoi220049r38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms.","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"hoi220049r39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"issue":"10","key":"hoi220049r40","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/00004872-198810000-00003","article-title":"The effect of atrial natriuretic factor on urinary albumin and beta 2-microglobulin excretion in man.","volume":"6","author":"McMurray","year":"1988","journal-title":"J Hypertens"},{"issue":"2","key":"hoi220049r41","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/0006-291X(90)90744-8","article-title":"Atrial natriuretic peptide regulation of endothelial permeability is mediated by cGMP.","volume":"172","author":"Lofton","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"hoi220049r42","first-page":"S198","article-title":"Mechanism of decreased albuminuria caused by angiotensin converting enzyme inhibitor in early diabetic nephropathy.","volume":"63","author":"Imanishi","year":"1997","journal-title":"Kidney Int Suppl"},{"issue":"18","key":"hoi220049r43","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.jacc.2012.07.036","article-title":"Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction.","volume":"60","author":"Akiyama","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"hoi220049r44","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1161\/01.CIR.93.4.704","article-title":"Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart.","volume":"93","author":"Torre-Amione","year":"1996","journal-title":"Circulation"},{"issue":"1","key":"hoi220049r45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/ajplegacy.1949.157.1.1","article-title":"Effect of increased renal venous pressure on renal function.","volume":"157","author":"Blake","year":"1949","journal-title":"Am J Physiol"},{"issue":"1","key":"hoi220049r46","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.kint.2018.08.024","article-title":"Aldosterone induces albuminuria via matrix metalloproteinase-dependent damage of the endothelial glycocalyx.","volume":"95","author":"Butler","year":"2019","journal-title":"Kidney Int"},{"issue":"4","key":"hoi220049r47","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1159\/000501081","article-title":"A potential mechanism of cardio-renal protection with sodium-glucose cotransporter 2 inhibitors: amelioration of renal congestion.","volume":"44","author":"Kuriyama","year":"2019","journal-title":"Kidney Blood Press Res"},{"issue":"4","key":"hoi220049r48","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/path.v256.4","article-title":"Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A\/caveolin-1\/PV-1 signaling pathway.","volume":"256","author":"Locatelli","year":"2022","journal-title":"J Pathol"},{"key":"hoi220049r49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174715","article-title":"Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-?B activation in human endothelial cells and differentiated macrophages.","volume":"918","author":"Abdollahi","year":"2022","journal-title":"Eur J Pharmacol"},{"issue":"24","key":"hoi220049r50","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"hoi220049r51","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function.","volume":"138","author":"Neuen","year":"2018","journal-title":"Circulation"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2796744\/jamacardiology_ferreira_2022_oi_220049_1667925985.04207.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T16:04:08Z","timestamp":1668009848000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2796744"}},"subtitle":["A Secondary Analysis of EMPEROR-Pooled"],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2022.2924","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}